HealthTronics bids for EndoCare
This article was originally published in The Gray Sheet
Executive SummaryIn a letter to Endocare's board of directors, released after the markets closed on Aug. 6, HealthTronics says it wants to buy the cryosurgery device company for $2.28 per share, about a 20% premium over Endocare's Aug. 6 closing stock price. Endocare responds that its board will review the unsolicited bid and consult with advisers. Both companies have a focus on prostate cancer. In second-quarter earnings released Aug. 6, Endocare's sales were flat at $7.9 million
You may also be interested in...
The pharmaceutical industry will be watching carefully as the EU Court of Justice deliberates on whether to deny or widen the granting of supplementary protection certificates on new therapeutic indications of authorized medicines.
Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge related to its generic version of the NuvaRing contraceptive. However, the company’s shares jumped on a robust underlying performance that was praised by analysts.